Several other research firms also recently issued reports on ZTS. Jefferies Group reaffirmed a buy rating and issued a $60.00 price objective on shares of Zoetis in a research note on Tuesday, August 23rd. Guggenheim reaffirmed a positive rating and issued a $60.00 price objective on shares of Zoetis in a research note on Monday, August 22nd. Citigroup Inc. downgraded Zoetis from a buy rating to a neutral rating and upped their price objective for the company from $46.00 to $50.00 in a research note on Friday, June 10th. They noted that the move was a valuation call. Barclays PLC upped their price objective on Zoetis from $45.00 to $49.00 and gave the company an equal weight rating in a research note on Thursday, August 4th. Finally, Credit Suisse Group AG reaffirmed a focus list rating and issued a $60.00 price objective on shares of Zoetis in a research note on Wednesday, September 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. Zoetis presently has a consensus rating of Buy and a consensus target price of $55.27.
Shares of Zoetis (NYSE:ZTS) opened at 51.02 on Thursday. Zoetis has a one year low of $38.26 and a one year high of $52.64. The company has a market cap of $25.26 billion, a price-to-earnings ratio of 39.74 and a beta of 1.01. The firm’s 50-day moving average is $51.27 and its 200-day moving average is $48.26.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.05. The business earned $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Zoetis had a return on equity of 77.58% and a net margin of 13.15%. Zoetis’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 earnings per share. Analysts expect that Zoetis will post $1.90 EPS for the current fiscal year.
In other Zoetis news, insider Andrew Fenton sold 13,870 shares of the firm’s stock in a transaction dated Friday, September 2nd. The stock was sold at an average price of $51.25, for a total value of $710,837.50. Following the completion of the transaction, the insider now owns 17,719 shares in the company, valued at approximately $908,098.75. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael B. Mccallister bought 2,000 shares of the business’s stock in a transaction on Tuesday, September 6th. The stock was bought at an average price of $51.34 per share, with a total value of $102,680.00. The disclosure for this purchase can be found here. Insiders own 0.05% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ZTS. Evercore Wealth Management LLC increased its position in shares of Zoetis by 12.0% in the second quarter. Evercore Wealth Management LLC now owns 3,402 shares of the company’s stock valued at $161,000 after buying an additional 365 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Zoetis by 440.6% in the second quarter. Macquarie Group Ltd. now owns 90,200 shares of the company’s stock valued at $4,281,000 after buying an additional 73,516 shares in the last quarter. Williams Jones & Associates LLC increased its position in shares of Zoetis by 2,171.9% in the second quarter. Williams Jones & Associates LLC now owns 15,903 shares of the company’s stock valued at $755,000 after buying an additional 15,203 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Zoetis during the second quarter valued at approximately $875,000. Finally, Kentucky Retirement Systems bought a new position in shares of Zoetis during the second quarter valued at approximately $1,842,000. Institutional investors and hedge funds own 93.12% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.